LinkedIn · Jul 2025
Aimée DeGolyer said she would speak on a precision medicine panel and pitch REPROSENT at the 2025 Silicon Valley Cancer Tech Conference.
Activating an overlooked force in medicine - the patient.
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
REPROSENT is an early-stage U.S. oncology digital health / biotech company that turns patient-reported symptoms and caregiver check-ins into longitudinal, dose-aware, computable data for safer trials, tolerability signal, and treatment decisions.
Primary product
Human-signal layer for oncology: a patient/caregiver symptom-capture and tolerability-data platform for trials and care programs.
Founded
2020
Headquarters
Los Gatos, California, United States
Team size
1-10
Work style
Remote
Industry
Biotechnology Research
Sub-industry
Oncology digital health / patient-reported outcomes platform
Offices
0 jobs at REPROSENT
Check back later for new openings
Business model
Leadership
Founder & CEO
Co-founder & CTO
Head of Operations
Founding Investor, Advisor
Mission-driven, patient-centric, founder-led startup focused on oncology outcomes, clinical workflow reduction, and better tolerability data; small team with a research-heavy, globally oriented posture.
Work style
Remote
Pricing
Subscription-based B2B software / SaaS
Differentiators
Technology
Customers
Competitors
Estimated revenue
Roughly $1M-$1.3M annual revenue / ARR based on public third-party estimates
LinkedIn · Jul 2025
Aimée DeGolyer said she would speak on a precision medicine panel and pitch REPROSENT at the 2025 Silicon Valley Cancer Tech Conference.
LinkedIn · Oct 2024
Aimée DeGolyer announced REPROSENT’s selection into Cancer Patient Lab’s inaugural CancerHacker Lab accelerator program.
Astellas Newsroom · Aug 2022
Astellas named Aimée DeGolyer / REPROSENT the 2022 C3 Grand Prize winner and awarded a $100,000 grant for the company’s patient-centric oncology app.
Becker's Hospital Review · Aug 2022
Coverage of REPROSENT’s Astellas prize win and the app’s goal of improving patient inclusion, symptom capture, and clinician communication in oncology.